Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease

Jeroen Hoogland; Rob M.A. De Bie; Caroline H. Williams-Gray; Dino Muslimović; Ben Schmand; Bart Post

doi:10.1002/mds.23319

Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease

Jeroen Hoogland, Rob M.A. De Bie, Caroline H. Williams-Gray, Dino Muslimović, Ben Schmand, Bart Post^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Cognitive dysfunction is one of the most incapacitating non-motor symptoms of Parkinson's disease (PD). Some cognitive deficits are thought to be related to abnormal dopamine homeostasis. The latter is influenced by catechol-O-methyltransferase (COMT), an enzyme that degrades dopamine. Previous research suggests a relationship between the COMT val158met functional polymorphism (SNP) and measures of executive function. We evaluated this hypothesis in a cohort of PD patients with an extensive neuropsychological test battery. Cognitive assessment and COMT genotyping were performed in 153 early PD patients from outpatient clinics general hospitals in the Netherlands. Our results do not support a direct effect of COMT val158met genotype on performance on neuropsychological measures of attention and executive function, but they suggest that genotype may interact with dopaminergic medication use to influence cognitive ability.

Original language	English
Pages (from-to)	2550-2554
Number of pages	5
Journal	Movement Disorders
Volume	25
Issue number	15
DOIs	https://doi.org/10.1002/mds.23319
Publication status	Published - Nov 2010

Access to Document

10.1002/mds.23319

Cite this

@article{27bf7c52c6794bfe8a1f2bded515a7e5,

title = "Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease",

abstract = "Cognitive dysfunction is one of the most incapacitating non-motor symptoms of Parkinson's disease (PD). Some cognitive deficits are thought to be related to abnormal dopamine homeostasis. The latter is influenced by catechol-O-methyltransferase (COMT), an enzyme that degrades dopamine. Previous research suggests a relationship between the COMT val158met functional polymorphism (SNP) and measures of executive function. We evaluated this hypothesis in a cohort of PD patients with an extensive neuropsychological test battery. Cognitive assessment and COMT genotyping were performed in 153 early PD patients from outpatient clinics general hospitals in the Netherlands. Our results do not support a direct effect of COMT val158met genotype on performance on neuropsychological measures of attention and executive function, but they suggest that genotype may interact with dopaminergic medication use to influence cognitive ability.",

keywords = "Catechol-O-methyltransferase, Cognitive deficits, Executive function, Parkinson's disease",

author = "Jeroen Hoogland and {De Bie}, {Rob M.A.} and Williams-Gray, {Caroline H.} and Dino Muslimovi{\'c} and Ben Schmand and Bart Post",

year = "2010",

month = nov,

doi = "10.1002/mds.23319",

language = "English",

volume = "25",

pages = "2550--2554",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "15",

}

TY - JOUR

T1 - Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease

AU - Hoogland, Jeroen

AU - De Bie, Rob M.A.

AU - Williams-Gray, Caroline H.

AU - Muslimović, Dino

AU - Schmand, Ben

AU - Post, Bart

PY - 2010/11

Y1 - 2010/11

N2 - Cognitive dysfunction is one of the most incapacitating non-motor symptoms of Parkinson's disease (PD). Some cognitive deficits are thought to be related to abnormal dopamine homeostasis. The latter is influenced by catechol-O-methyltransferase (COMT), an enzyme that degrades dopamine. Previous research suggests a relationship between the COMT val158met functional polymorphism (SNP) and measures of executive function. We evaluated this hypothesis in a cohort of PD patients with an extensive neuropsychological test battery. Cognitive assessment and COMT genotyping were performed in 153 early PD patients from outpatient clinics general hospitals in the Netherlands. Our results do not support a direct effect of COMT val158met genotype on performance on neuropsychological measures of attention and executive function, but they suggest that genotype may interact with dopaminergic medication use to influence cognitive ability.

AB - Cognitive dysfunction is one of the most incapacitating non-motor symptoms of Parkinson's disease (PD). Some cognitive deficits are thought to be related to abnormal dopamine homeostasis. The latter is influenced by catechol-O-methyltransferase (COMT), an enzyme that degrades dopamine. Previous research suggests a relationship between the COMT val158met functional polymorphism (SNP) and measures of executive function. We evaluated this hypothesis in a cohort of PD patients with an extensive neuropsychological test battery. Cognitive assessment and COMT genotyping were performed in 153 early PD patients from outpatient clinics general hospitals in the Netherlands. Our results do not support a direct effect of COMT val158met genotype on performance on neuropsychological measures of attention and executive function, but they suggest that genotype may interact with dopaminergic medication use to influence cognitive ability.

KW - Catechol-O-methyltransferase

KW - Cognitive deficits

KW - Executive function

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=78349274517&partnerID=8YFLogxK

U2 - 10.1002/mds.23319

DO - 10.1002/mds.23319

M3 - Article

C2 - 20878993

AN - SCOPUS:78349274517

SN - 0885-3185

VL - 25

SP - 2550

EP - 2554

JO - Movement Disorders

JF - Movement Disorders

IS - 15

ER -

Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease

Abstract

Access to Document

Other files and links

Cite this